Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Why do BCL-2 inhibitors work and where should we use them in the clinic?
Joan Montero, Antony Letai
Cell Death and Differentiation (2017) Vol. 25, Iss. 1, pp. 56-64
Open Access | Times Cited: 288

Showing 1-25 of 288 citing articles:

Emerging connectivity of programmed cell death pathways and its physiological implications
Sammy Bedoui, Marco J. Herold, Andreas Strasser
Nature Reviews Molecular Cell Biology (2020) Vol. 21, Iss. 11, pp. 678-695
Closed Access | Times Cited: 714
Mitochondrial dynamics in adaptive and maladaptive cellular stress responses
Verónica Eisner, Martin Picard, György Hajnóczky
Nature Cell Biology (2018) Vol. 20, Iss. 7, pp. 755-765
Open Access | Times Cited: 523
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams, Suzanne Cory
Cell Death and Differentiation (2017) Vol. 25, Iss. 1, pp. 27-36
Open Access | Times Cited: 462
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron, Matthew A. Belmonte, Ammar Adam, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 436
The role of BCL-2 family proteins in regulating apoptosis and cancer therapy
Shanna Qian, Wei Zhong, Wanting Yang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 434
Effective drug combinations in breast, colon and pancreatic cancer cells
Patricia Jaaks, Elizabeth A. Coker, Daniël J. Vis, et al.
Nature (2022) Vol. 603, Iss. 7899, pp. 166-173
Open Access | Times Cited: 300
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Delphine Mérino, Gemma L. Kelly, Guillaume Lessène, et al.
Cancer Cell (2018) Vol. 34, Iss. 6, pp. 879-891
Open Access | Times Cited: 265
Cell death in pancreatic cancer: from pathogenesis to therapy
Xin Chen, Herbert J. Zeh, Rui Kang, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 11, pp. 804-823
Closed Access | Times Cited: 241
Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy
Tareq Saleh, Sarah Bloukh, Valerie J. Carpenter, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 822-822
Open Access | Times Cited: 227
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Isha Kapoor, Juraj Bodo, Brian T. Hill, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 11
Open Access | Times Cited: 196
3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis
Nobuaki Takahashi, Patricia Cho, Laura M. Selfors, et al.
Molecular Cell (2020) Vol. 80, Iss. 5, pp. 828-844.e6
Open Access | Times Cited: 152
Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions
Nguyễn Thị Thanh Nhàn, Tohru Yamada, Kaori Yamada
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12931-12931
Open Access | Times Cited: 55
Bcl-2 pathway inhibition in solid tumors: a review of clinical trials
Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis‐Alexios Koumprentziotis, et al.
Clinical & Translational Oncology (2023) Vol. 25, Iss. 6, pp. 1554-1578
Open Access | Times Cited: 53
Targeting the Bcl-2 Family in B Cell Lymphoma
Clare M. Adams, Sean Clark-Garvey, Pierluigi Porcu, et al.
Frontiers in Oncology (2019) Vol. 8
Open Access | Times Cited: 136
MCL-1 inhibition in cancer treatment
Weiguo Xiang, Chao‐Yie Yang, Longchuan Bai
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 7301-7314
Open Access | Times Cited: 134
Senescence in Wound Repair: Emerging Strategies to Target Chronic Healing Wounds
Holly N. Wilkinson, Matthew J. Hardman
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 127
Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
Simona D’Aguanno, Donatella Del Bufalo
Cells (2020) Vol. 9, Iss. 5, pp. 1287-1287
Open Access | Times Cited: 123
Recent advances in the development of Mcl-1 inhibitors for cancer therapy
Alexander W. Hird, Adriana E. Tron
Pharmacology & Therapeutics (2019) Vol. 198, pp. 59-67
Open Access | Times Cited: 122
Balancing Apoptosis and Autophagy for Parkinson’s Disease Therapy: Targeting BCL-2
Jia Liu, Weijing Liu, Hui Yang
ACS Chemical Neuroscience (2018) Vol. 10, Iss. 2, pp. 792-802
Closed Access | Times Cited: 119
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 47, pp. 100646-100646
Closed Access | Times Cited: 112
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Prashanthi Ramesh, Jan Paul Medema
APOPTOSIS (2020) Vol. 25, Iss. 5-6, pp. 305-320
Open Access | Times Cited: 101
Single-Cell Transcriptomics Identifies the Adaptation of Scart1+ Vγ6+ T Cells to Skin Residency as Activated Effector Cells
Likai Tan, Inga Sandrock, Ivan Odak, et al.
Cell Reports (2019) Vol. 27, Iss. 12, pp. 3657-3671.e4
Open Access | Times Cited: 98
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL
Kamil Bojarczuk, Kirsty Wienand, Jeremy Ryan, et al.
Blood (2018) Vol. 133, Iss. 1, pp. 70-80
Open Access | Times Cited: 87
STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment
Steven Lohard, Nathalie Bourgeois, Laurent Maillet, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 85
Predicting and affecting response to cancer therapy based on pathway-level biomarkers
Rotem Ben‐Hamo, A. Berger, Nancy Gavert, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 80
Page 1 - Next Page

Scroll to top